(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺
生物活性靶点体外研究体内研究 用途与合成方法 MSDS (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺价格(试剂级) 上下游产品信息
| 中文名称 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 |
|---|---|
| 中文同义词 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺;化合物 T16937;(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 |
| 英文名称 | ST 2825 |
| 英文同义词 | (2R,4'R,8'aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxospiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide;ST 2825;ST 2825;ST2825;Spiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide, 1-[2-[4-[[2-(2,4-dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxo-, (2R,4'R,8'aR)-;(2R,4'R,8a'R)-1-(2-(4-(2-(2,4-Dichlorophenoxy)acetamido)phenyl)acetyl)-6'-oxotetrahydro-2'H,6'H-spiro[pyrrolidine-2,7'-pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide |
| CAS号 | 894787-30-5 |
| 分子式 | C27H28Cl2N4O5S |
| 分子量 | 591.51 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 894787-30-5.mol |
| 结构式 | ![(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 结构式](CAS/20180906/GIF/894787-30-5.gif) |
(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 性质
| 沸点 | 939.0±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.51±0.1 g/cm3(Predicted) |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 12.86±0.70(Predicted) |
(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 用途与合成方法
ST 2825 是一种特异的 MyD88 二聚化抑制剂。ST 2825 干扰 MyD88 对 IRAK1 和 IRAK4 的募集，抑制 IL-1β 介导的 NF-κB 转录活性。
MyD88
ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825.
ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-50937 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 ST 2825 | 894787-30-5 | 1mg | 3302元 |
| 2023/03/20 | HY-50937 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 ST 2825 | 894787-30-5 | 5mg | 11346元 |